A systematic review and meta-analysis of 158 oncology AI studies found that only 9% of deep learning models for cancer treatment prediction had reached clinical implementation, despite pooled AUCs of 0.823 for internal validation and 0.787 for external validation. The review, including 89 studies in quantitative synthesis, suggests current performance is promising but not yet practice-ready because of high heterogeneity, frequent bias, and limited external validation.

Why It Matters To Your Practice

• Deep learning models are showing useful discrimination for predicting treatment response and outcomes across multiple cancer types and therapies.

• But most models remain far from bedside use, with implementation lagging well behind publication volume.

• For clinicians, that means many tools may look accurate in papers yet still lack the validation needed for reliable real-world decision support.

Clinical Implications

• Be cautious about adopting oncology AI tools based only on internal validation metrics.

• External validation performance dropped versus internal validation, highlighting likely overestimation in development cohorts.

• Multimodal and Transformer-based models performed better overall, but architecture alone does not overcome bias, reporting gaps, or workflow barriers.

Insights

• This was the first cross-cancer meta-analytic synthesis of deep learning for treatment prediction across tumor types and model classes.

• Substantial heterogeneity (I2 greater than 70%) means pooled accuracy should be viewed as a feasibility signal, not a universal benchmark.

• Common weaknesses included methodological inconsistency, high risk of bias, and sparse evidence of clinical utility.

The Bottom Line

• AI in oncology is advancing faster than implementation.

• Until models are transparently reported, externally validated, and tested in clinical workflows, clinicians should treat most published tools as investigational rather than deployable.

• The near-term opportunity is selective use in rigorously evaluated settings, not broad routine adoption.